Abstract
Background
Persistent epithelial defects (PEDs) are challenging corneal conditions with prolonged non-healing. Commonly associated with dry eye disease and neurotrophic keratopathy, PEDs can lead to severe complications. Topical insulin has emerged as a therapeutic option, promoting epithelial healing.
Methods
We searched Medline, Embase, Web of Science, and Cochrane Library databases following PRISMA guidelines for studies reporting topical insulin for PEDs of any etiology and corneal epithelial defect (CEDs) post-vitrectomy. Healing time, complete wound healing (CWH), epithelization failure (EF), and epithelial healing rate were our analysis outcomes. Statistical analyses employed random-effects models and I² statistic.
Results
Thirteen studies involving 390 eyes were included. Mean healing time for all conditions was 20.68 days (95% CI: 11.60, 29.76) with significant heterogeneity. The pooled CWH rate was 94% (95% CI: 0.87, 0.98), with an odds ratio of 5.41 favoring topical insulin over the control group. EF was low at 5% (95% CI: 0, 0.13), and the epithelial healing rate was 0.82 mm²/hour (95% CI: 0.02, 1.62). Subgroup analyses revealed variations.
Conclusions
Topical insulin is effective in corneal wound healing, demonstrating high CWH rates and low failure rates. Further well-controlled studies are needed to validate these findings and assess long-term outcomes.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
